Bioventix PLC

Capital Structure and Liquidity Bioventix maintains a strong liquidity position with a current ratio of 9.17, indicating ample short-term assets to cover liabilities. The company has no long-term debt and a debt-to-equity ratio of 0.0, reflecting a conservative capital structure. Despite a high price-to-book ratio of 768.91, the company's liquidity risk is assessed as low. ### Profitability and Returns The company's profitability is robust, with a gross profit margin of 90.86% and a net profit margin of 57.82%. Return on equity (ROE) stands at 65.66%, significantly outperforming the industry median for biotechnology firms. Return on assets (ROA) is also strong at 58.96%, indicating efficient use of assets to generate profit. ### Segments and Geographic Exposure Bioventix operates as a single business segment, focusing on the development and supply of monoclonal antibodies for clinical diagnostics. The company's revenue is concentrated in the United Kingdom, with no disclosed geographic diversification. This concentration may expose the company to regional economic or regulatory risks. ### Growth Trajectory The company's revenue in the latest period was 13.12 million GBP, slightly exceeding the mean analyst estimate of 12.50 million GBP. Analysts have set a uniform price target of 3,900 GBP, suggesting a potential upside of 129.41% from the current market price of 1,700 GBP. The company's free cash flow was negative at -536,780 GBP, primarily due to capital expenditures of -19,190 GBP. ### Risk Factors The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the high price-to-earnings ratio of 1,171.12 suggests potential overvaluation, and the company's reliance on a single product line and geographic market may pose long-term risks. ### Recent Events Recent financial filings show consistent revenue and profit performance, with the last actual EPS of 1.43 GBP slightly exceeding the mean analyst estimate of 1.36 GBP. No significant recent events or regulatory actions have been disclosed that would impact the company's operations or valuation.